Clinical Trials Directory

Trials / Completed

CompletedNCT05927415

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

A Phase 1, Open-label, Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10 mg/kg Single Dose Administered in Participants With Renal Impairment

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
33 (actual)
Sponsor
argenx · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

A study to test how kidney problems influence the blood concentrations of efgartigimod

Conditions

Interventions

TypeNameDescription
BIOLOGICALEfgartigimod IVIntravenous infusion of efgartigimod

Timeline

Start date
2023-07-17
Primary completion
2024-06-12
Completion
2024-06-12
First posted
2023-07-03
Last updated
2024-06-26

Locations

2 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT05927415. Inclusion in this directory is not an endorsement.